H.R. 5269

119 HR 5269 IH: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025
 U.S. House of Representatives
 2025-09-10
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 5269  IN THE HOUSE OF REPRESENTATIVES   September 10, 2025   Mr. Hudson  (for himself,  Mr. Peters ,  Mr. Bilirakis ,  Mr. Krishnamoorthi ,  Mr. Fitzpatrick ,  Mr. Carter of Georgia ,  Mr. Joyce of Pennsylvania ,  Mr. Ciscomani ,  Mr. Davis of North Carolina ,  Ms. Davids of Kansas ,  Ms. Ross ,  Mr. Balderson , and  Ms. Sewell ) introduced the following bill; which was referred to the  Committee on Energy and Commerce , and in addition to the Committee on  Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned   A BILL
To amend title XVIII of the Social Security Act to provide long-term stability for Medicare beneficiary access to clinical diagnostic laboratory tests by improving the accuracy of, and feasibility of data collection for, the private payor-based fee schedule payment rates applied under the Medicare program for such tests, and for other purposes.
1.
Short title
This Act may be cited as the   Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025   or the   RESULTS Act  .
2.
Improving the accuracy and data collection feasibility of the private payor-based Medicare payment rates for clinical diagnostic laboratory tests
(a)
Acquiring data for widely available non-Advanced diagnostic laboratory tests from a qualifying comprehensive claims database of an independent national nonprofit entity
Section 1834A(a) of the Social Security Act ( 42 U.S.C. 1395m–1(a) ) is amended—
(1)
in paragraph (1)—
(A)
in subparagraph (A)—
(i)
by striking
requirements .—Subject to subparagraph (B)  and inserting
requirements .—
(i)
In general
Subject to subparagraph (B) and except as provided for in clause (ii)
  ;
(ii)
in clause (i), as added by clause (i) of this subparagraph—
(I)
by striking  paragraph (2)  and inserting  paragraph (2)(A) ;
(II)
by inserting  , in accordance with the provisions of this section,  before  report to the Secretary ;
(III)
by striking  applicable information (as defined in paragraph (3)) for a data collection period (as defined in paragraph (4))  and inserting
applicable information (as defined in paragraph (3))—
(I)
for a data collection period (as defined in paragraph (4)) beginning before January 1, 2027,
  ;
(IV)
by striking the period at the end and inserting  ; and ; and
(V)
by adding at the end the following new subclause:
(II)
for a data collection period beginning on or after January 1, 2027, for each clinical diagnostic laboratory test for which final payment is made under this part to the laboratory during such period.
  ; and
(iii)
by adding at the end the following new clause;
(ii)
Collection and submission of data
(I)
In general
With respect to data collection periods for reporting periods beginning on or after January 1, 2028, and for purposes of this section, in the case of a widely available non-ADLT clinical diagnostic laboratory test (as defined in paragraph (2)(E)), the Secretary shall collect and use applicable information from a qualifying comprehensive claims database (as defined in paragraph (2)(C)) of a qualifying independent claims data entity (as defined in paragraph (2)(D)) with which the Secretary has in effect a contract under subclause (II) for each such test furnished during the respective data collection period and for which final payment is made under this part during the year in which such data collection period occurs.
(II)
Contract with qualifying independent claims data entity for access to
  applicable information
As soon as practicable after the date of enactment of this clause, the Secretary shall identify and enter into a contract with a qualifying independent claims data entity for the purpose of, with respect to widely available non-ADLT clinical diagnostic laboratory tests furnished during a data collection period, such entity reporting to the Secretary applicable information from a qualifying comprehensive claims database of the entity for such tests for which final payment is made under this part during the year in which such data collection period occurs and for which there is applicable information within such database for such period.
  .
(B)
in subparagraph (B)—
(i)
in clause (i), by striking  2025  and inserting  2027 ;
(ii)
in clause (ii), by striking  beginning January 1, 2026, and ending March 31, 2026  and inserting  beginning January 1, 2028, and ending March 31, 2028 ; and
(iii)
in clause (iii), by striking  three years  and inserting  4 years ;
(2)
in paragraph (2)—
(A)
by striking
Definition of applicable laboratory .—In this section, the term  applicable laboratory  means  and inserting
Definitions .—In this section:
(A)
Applicable laboratory
(i)
Reporting periods before 2028
With respect to reporting periods beginning before January 1, 2028, the term  applicable laboratory  means
  ;
(B)
in subparagraph (A), as inserted by subparagraph (A) of this paragraph—
(i)
in clause (i), in the second sentence, by striking  paragraph  and inserting  clause ; and
(ii)
by adding at the end the following new clause:
(ii)
Reporting periods beginning during 2028 and subsequent years
With respect to reporting periods beginning on or after January 1, 2028, the term  applicable laboratory  shall have the meaning given such term in section 414.502 of title 42, Code of Federal Regulations, as in effect on May 1, 2025, except without application of paragraph (3) of such section.
  ; and
(C)
by adding at the end the following new subparagraphs:
(B)
Non-widely available non-ADLT clinical diagnostic laboratory test
The term  non-widely available non-ADLT clinical diagnostic laboratory test  means, with respect to a reporting period, a clinical diagnostic laboratory test that is not an advanced diagnostic laboratory test and that is not described in subparagraph (E).
(C)
Qualifying independent claims data entity
The term  qualifying independent claims data entity  means an entity that satisfies each of the following criteria:
(i)
The entity is a national nonprofit organization that is not affiliated with any Government agency, insurance issuer, group health plan, provider of services or supplier, or other organization in the health care sector.
(ii)
The entity collects data and maintains a qualifying comprehensive claims database (as defined in subparagraph (D)).
(iii)
The entity is certified by the Secretary to be a qualified entity (as defined in paragraph (2) of section 1874(e)) with respect to having access to data described in paragraph (3) of such section.
(iv)
The entity, with respect to all data included in the qualifying comprehensive claims database of the entity, complies with all applicable Federal and State privacy and security requirements, including HIPAA privacy and security law (as defined in section 3009 of the Public Health Service Act).
(v)
The entity applies quality assurance processes to validate all data that is included in the qualifying comprehensive claims database of the entity, including comprehensive statistical testing.
(D)
Qualifying comprehensive claims database
The term  qualifying comprehensive claims database  means an independent database of private payor claims data, which—
(i)
includes at least 50,000,000,000 claims from more than 50 private payors and claims administrators;
(ii)
is a statistically significant repository of claims data that is representative for all 50 States and the District of Columbia;
(iii)
includes only data that is validated by quality assurance processes, including comprehensive statistical testing;
(iv)
complies with all applicable Federal and State privacy and security requirements, as described in subparagraph (C)(iv);
(v)
provides for version control of claims to enable the collation and submission, for purposes of this section, of only claims representative of final payment amounts; and
(vi)
includes claims data with respect to widely available non-ADLT clinical diagnostic laboratory tests.
(E)
Widely available non-ADLT clinical diagnostic laboratory test
The term  widely available non-ADLT clinical diagnostic laboratory test  means, with respect to a reporting period, a clinical diagnostic laboratory test that is not an advanced diagnostic laboratory test and for which, during the first 6 months of the year immediately preceding the data collection period for such reporting period, the number of providers of services and suppliers receiving payments under this section (as determined by the Secretary using the national provider identifier of the provider of services or supplier on the claim submitted for payment under this part for such test) exceeds 100.
  ;
(3)
in paragraph (5)—
(A)
by inserting  final  after  The ; and
(B)
by inserting  or from a qualifying comprehensive claims database pursuant to paragraph (1)(A)(ii)  after  reported by a laboratory under this subsection ;
(4)
in paragraph (6)—
(A)
by inserting  (or, with respect to a widely available non-ADLT clinical diagnostic laboratory test, the qualifying comprehensive claims database of the qualifying independent claims data entity with a contract under paragraph (1)(A)(ii))  after  In the case where an applicable laboratory ;
(B)
by striking  payment rate  each place it appears and inserting  final payment rate ;
(C)
by inserting  (and such different payment rates do not relate to the same claim)  after  for the same payor for the same test ; and
(D)
by inserting  or qualifying independent claims data entity, as applicable,  after  the applicable laboratory ;
(5)
in paragraph (9)(A), by inserting  required to be reported by such laboratory  after  in reporting information ;
(6)
in paragraph (10)—
(A)
by striking  by a laboratory  after  information disclosed ; and
(B)
by inserting  by a laboratory or the qualifying independent claims data entity with a contract under paragraph (1)(A)(ii)  after  under this subsection ; and
(7)
in paragraph (12)—
(A)
by striking
Regulations .—Not later than June 30, 2015,  and inserting
Regulations .—
(A)
For data collection periods before 2027
Not later than June 30, 2015, for data collection periods beginning before January 1, 2027,
  ; and
(B)
by adding at the end the following new subparagraph:
(B)
For data collection periods beginning with 2027
Not later than December 31, 2026, the Secretary shall establish through notice and comment rulemaking parameters for data collection periods beginning on or after January 1, 2027.
  .
(b)
Incorporating data collection improvements into private payor-Based Medicare payment
  rates for clinical diagnostic laboratory tests that are not advanced diagnostic laboratory
  tests
(1)
Calculation of weighted median of private payor-based rates
Section 1834A(b)(2) of the Social Security Act ( 42 U.S.C. 1395m–1(b)(2) ) is amended—
(A)
by inserting  and, in the case of widely available non-ADLT clinical diagnostic laboratory tests, with respect to data collection periods for reporting periods beginning on or after January 1, 2028, for each such test furnished by an applicable laboratory with respect to which there is applicable information made available to the Secretary pursuant to paragraph (1)(A)(ii)) of such subsection  after  under subsection (a) for a data collection period ; and
(B)
by inserting  final  before  payment rates reported .
(2)
Default adjustment in cases of widely available non-ADLT clinical diagnostic
  laboratory tests for periods for which there is no contract with a qualifying
  independent claims entity or no applicable information in the qualifying comprehensive
  claims database
Section 1834A(b) of the Social Security Act ( 42 U.S.C. 1395m–1(b) ) is amended—
(A)
in paragraph (1)(A), by striking  paragraph (3)  and inserting  paragraphs (3) and (6) ; and
(B)
by adding at the end the following new paragraph:
(6)
Default payment for widely available non-ADLT clinical diagnostic laboratory tests for periods for which there is no contract with an independent entity or with respect to which there is no data
(A)
In general
With respect to data collection periods for reporting periods beginning on or after January 1, 2028, in the case of a widely available non-ADLT clinical diagnostic laboratory test with respect to which subsection (c) does not apply, if a circumstance described in subparagraph (B) applies with respect to such a reporting period and such a clinical diagnostic laboratory test, payment for such test under this section for a year beginning during the qualified rate period described in subparagraph (C), shall be equal to the amount of payment for such clinical diagnostic laboratory test under this section for the previous year, increased by the percentage increase in the Consumer Price Index for all urban consumers (all items; United States city average) over the previous year.
(B)
Circumstances described
For purposes of subparagraph (A), with respect to a data collection period and a widely available non-ADLT clinical diagnostic laboratory test, the circumstances described in this subparagraph are if the Secretary—
(i)
is not able to enter into a contract under subsection (a)(1)(A)(ii) with a qualifying independent claims data entity with respect to such data collection period; or
(ii)
determines that there is no applicable information with respect to such clinical diagnostic laboratory test and data collection period in the qualifying comprehensive claims database of such qualifying independent claims data entity.
(C)
Qualified rate period described
For purposes of subparagraph (A), the qualified rate period, with respect to a data collection period and a widely available non-ADLT clinical diagnostic test to which a circumstance described in subparagraph (B) applies, is the period—
(i)
beginning on the first day of the second year following the first data collection period with respect to which such circumstance applies with respect to such test; and
(ii)
ending with the last day of the year following the first data collection period with respect to which such circumstance no longer applies with respect to such test.
  .
(3)
Payment in cases in which there is no reported applicable information for
  non-widely available non-ADLTs
Section 1834A of the Social Security Act ( 42 U.S.C. 1395m–1 ), is amended—
(A)
in subsection (b), as amended by paragraph (2)—
(i)
in paragraph (1)(A), by striking  paragraphs (3) and (6)  and inserting  paragraphs (3), (6), and (7) ; and
(ii)
by adding at the end the following new paragraph:
(7)
Payment for non-widely available non-ADLT clinical diagnostic laboratory tests for which there is no applicable information
(A)
In general
For determining payment under this subsection for a year in the case of a non-widely available non-ADLT clinical diagnostic laboratory test with respect to which subsection (c) does not apply, if the Secretary determines that no applicable information has been reported under subsection (a)(1)(A)(i) by any applicable laboratory for such test with respect to the most recent data collection period (beginning with data collection periods for reporting periods beginning on or after January 1, 2028), payment for such test under this section for such year shall be determined as follows:
(i)
In the case that a process described in subparagraph (B) was not applied pursuant to this subparagraph for determining payment for such test for a previous year with respect to such data collection period, payment for such test and year shall be determined using such a process.
(ii)
In the case that a process described in subparagraph (B) was applied pursuant to this subparagraph for determining payment for such test for a previous year with respect to such data collection period, payment for such test and year shall be equal to the amount of payment for such test under this section for the previous year.
(B)
Process described
For purposes of subparagraph (A), a process described in this subparagraph, with respect to a non-widely available non-ADLT clinical diagnostic laboratory test for which there is no reported data (as described in such subparagraph) with respect to a data collection period, is—
(i)
cross-walking (as described in section 414.508(a) of title 42, Code of Federal Regulations, or any successor regulation) to the most appropriate clinical diagnostic laboratory test under the fee schedule under this section during that period; or
(ii)
if no other clinical diagnostic laboratory test is comparable to the test for which there is no reported applicable information, according to the gapfilling process described in subsection (c)(2).
  ; and
(B)
in subsection (c)(3), by inserting  or subsection (b)(7)  after  under this subsection .
(4)
Publicly available explanation of payment rates
Section 1834A(b) of the Social Security Act ( 42 U.S.C. 1395m–1(b) ), as amended by paragraphs (2) and (3)(A), is amended by adding at the end the following new paragraph:
(8)
Explanation of payment rates
In the case of a clinical diagnostic laboratory test for which payment is made under this subsection, the Secretary shall make available to the public an explanation of the payment rate for such test, including any supporting data as may be necessary for a laboratory to assess the accuracy of the calculations.
  .
(5)
Technical correction clarifying period of application of market rates
Section 1834A(b)(4)(A) of the Social Security Act ( 42 U.S.C. 1395m–1(b)(4)(A) ) is amended by striking  until the year following  and inserting  through the year following .
(c)
Additional improvements To ensure updated, accurate market-Based data for clinical
  diagnostic laboratory tests
(1)
Updates to applicable information to better reflect final payment rates
Section 1834A(a)(3) of the Social Security Act ( 42 U.S.C. 1395m–1(a)(3) ) is amended—
(A)
in the heading, by inserting
and final payment rate   after
information  ;
(B)
in subparagraph (A)—
(i)
in the heading, by striking
In general   and inserting
Data collection periods before January 1, 2027  ; and
(ii)
in the matter preceding clause (i)—
(I)
by striking  subparagraph (B)  and inserting  subparagraph (C) ; and
(II)
by inserting  beginning before January 1, 2027  after  for a data collection period ;
(C)
by redesignating subparagraph (B) as subparagraph (C);
(D)
by inserting after subparagraph (A) the following new subparagraph:
(B)
Subsequent data collection periods
In this section, subject to subparagraph (C), for a data collection period beginning on or after January 1, 2027, the term  applicable information  means—
(i)
with respect to a widely available non-ADLT clinical diagnostic laboratory test furnished during such period—
(I)
the final payment rate (as determined in accordance with paragraph (5) and defined in subparagraph (D)) that was paid by each private payor for the test during the year in which such period occurs; and
(II)
the volume, for each such payor, of such test for which final payment was made during such year; and
(ii)
with respect to a non-widely available non-ADLT clinical diagnostic laboratory test or an advanced diagnostic laboratory test—
(I)
the final payment rate (as determined in accordance with paragraph (5) and defined in subparagraph (D)) that was paid by each private payor for the test during the data collection period; and
(II)
the volume, for each such payor, of such test for which final payment was made during such period.
  ; and
(E)
by inserting after subparagraph (C), the following new subparagraph:
(D)
Final payment rate
In this section, for a data collection period beginning on or after January 1, 2027, the term  final payment rate —
(i)
means—
(I)
with respect to a widely available non-ADLT clinical diagnostic laboratory test furnished during a data collection period, the last payment made for a test during the year in which the data collection period occurs; and
(II)
with respect to a non-widely available non-ADLT clinical diagnostic laboratory test or an advanced diagnostic laboratory test paid during a data collection period, the last payment made during the data collection period; and
(ii)
does not include—
(I)
denied payments;
(II)
payments under appeal or under review by the private payor;
(III)
payments made in error; or
(IV)
payments that are recouped by the private payor.
  .
(2)
Updating data collection periods
Section 1834A(a)(4)(B) of the Social Security Act ( 42 U.S.C. 1395m–1(a)(4)(B) ) is amended—
(A)
by striking  January 1, 2019  and inserting  January 1, 2027 ;
(B)
by striking  June 30, 2019  and inserting  June 30, 2027 ; and
(C)
by adding at the end the following new sentence:  In the case of the reporting period after the reporting period described in paragraph (1)(B)(ii) and each subsequent reporting period with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the term  data collection period  means the 6-month period beginning January 1st of the year preceding the year during which such reporting period begins. .
(3)
Ensuring data is market-based by excluding rates of Medicaid managed care
  organizations
Section 1834A(a)(8)(C) of the Social Security Act ( 42 U.S.C. 1395m–1(a)(8)(C) ) is amended by striking  A medicaid managed care organization  and inserting  With respect to data collection periods for reporting periods beginning before January 1, 2028, a medicaid managed care organization. .
(4)
Modifications to limits on payment reductions
Section 1834A(b)(3) of the Social Security Act ( 42 U.S.C. 1395m–1(b)(3) ) is amended—
(A)
in subparagraph (A), by striking  each of 2017 through 2028  and inserting  2017 and each subsequent year ;
(B)
in subparagraph (B)—
(i)
in clause (ii), by striking  2025  and inserting  2028 ; and
(ii)
in clause (iii), by striking  for each of 2026 through 2028, 15 percent  and inserting  for 2029 and each subsequent year, 5 percent ; and
(C)
in subparagraph (C)(ii), by inserting  laboratory  after  advanced diagnostic .
(5)
Sunsetting review limitations
Section 1834A(h)(1) of the Social Security Act ( 42 U.S.C. 1395m–1(h)(1) ) is amended by inserting  before January 1, 2029  before the period at the end.